Breast cancer deaths decline among young women across all racial and subtype groups

Breast cancer deaths decline among young women across all racial and subtype groups

From 2010 to 2020, breast cancer deaths among women aged 20 to 49 years decreased significantly across all breast cancer subtypes and racial/ethnic groups. Laut einer Analyse von Daten aus der Überwachung der Überwachung, der Epidemiologie und der Endergebnisse (Seher), die in der American Association for Cancer Research (AACR) (AACR) (AACR) -Annovember (ACR) -Annovember (ACR) -Annovember (ACR) -Annovember (ACR) -Annovember (ACR) -Annovember (ACR) -Annovial-Treffen, begann ein deutlicher Rückgang.

Breast cancer incidence rates in women ages 20 to 49 have increased over the past 20 years in most racial and ethnic groups. However, few studies have examined mortality data for patients in this age group, according to Adetunji Toriola, MD, PhD, MPH, MPH, professor in the Department of Mustice and Department of Public Health Sciences and Siteman Cancer Center at Washington University School of Medicine.

“Understanding recent mortality trends will allow us to assess progress over the years and inform where resources can be directed to reduce the burden of cancer in this age group,” explained Toriola, who presented the study.

Toriola and colleagues analyzed data from the SEER Program 17 registry, which included data on 11,661 deaths in women ages 20 to 49 between 2010 and 2020. Trends with Annual Percentage Changes (APC). In addition, they conducted relative survival analyzes by examining the 10-year survival rate for each group and subtype.

Across all subtypes and racial/ethnic groups, baseline incidence mortality decreased from 9.70 per 100,000 women in 2010 to 1.47/100,000 in 2020. Luminal A experienced the most pronounced decline of the four subtypes, with a decline for the entire period and the largest decline in 2017 (-32.88% APC). Triple-negative breast cancer followed a similar trend, with 2018 marking its largest decline (-32.82% APC).

Although the decline in incidence-based mortality was greatest for Luminal A, 10-year relative survival varied by age for women with this breast cancer subtype. In women aged 40 to 49 years, Luminal A had the highest 10-year survival, while in women aged 20 to 39 years, Luminal A (78.3%) had a lower 10-year survival than Luminal B (84.2%).

This was unexpected as Luminal A is generally the least aggressive subtype with the most favorable prognosis. This requires confirmation in other studies, but may suggest that luminal A tumors in women aged 20 to 39 years may represent a more biologically heterogeneous and potentially aggressive subgroup. “

Adetunji Toriola, MD, PhD, MPH, Professor, Department of Surgery and Division of Public Health Sciences and Siteman Cancer Center, Washington University School of Medicine

While incidence-based mortality declined for each of the racial/ethnic groups, non-Hispanic black women had the most mortality in 2010 (16.56/100,000) and 2020 (3.41/100,000) and non-Hispanic white women in 2010 (9.18/100,000) and 2020 (1.16/100,000). The declines for non-Hispanic Black women in 2016 (-24.15% APC), for non-Hispanic Asian/Pacific Islanders in 2013 (-18.46% APC), for Hispanic women in 2017 (-30.15% APC), and for non-Hispanic American Indians and Alaska Natives in 2018 (-47.97%) year In 2018 (-47.97%) in 2018 (-47.97%) in 2018 (-47.97%) they have in 2018 (-47.97%) in 2018 (47.97%) in 2018 (47.97%) in 2018 (47.97%).

The 10-year relative survival analysis found that non-Hispanic black women had the worst survival outcomes, while non-Hispanic white women and non-Hispanic Asian Pacific Islander women had the best women.

“We have made tremendous progress in reducing breast cancer mortality in young women, but there is still room for improvement, particularly in eliminating disparities,” Toriola said.

Toriola explained that the decline in treatment options observed after 2016, greater uptake of precision medicine, and expanded access to care and screening among women ages 40 to 49 likely reflect advances. For example, he mentioned how the broader introduction of CDK4/6 inhibitors and the optimization of endocrine therapy, which began receiving FDA approval and clinical introduction between 2015 and 2016, likely played a key role in improving mortality rates for hormone receptor-positive, HER2-negative cancers-including Luminal A.

“We must continue to conduct impactful research to ensure further reductions in breast cancer mortality, including exploring understanding tumor biology and the molecular mechanisms that drive carcinogenesis and treatment response in younger women,” Toriola said. “In addition, we must encourage and establish access to population-based screening for women aged 40 to 49 and targeted screening for younger women at high risk, and advocate for access to quality treatment and care for all women.”

Key limitations of this study include a 10-year follow-up period and a relatively lower number of breast cancer deaths in some racial/ethnic groups.

Funding for this study was provided by Washington University School of Medicine. Toriola declares no conflicts of interest.

Sources: